{"DataElement":{"publicId":"2680562","version":"1","preferredName":"Cancer and Leukemia Group B Patient Inclusion Clinical Trial Eligibility Criteria 40601 Type","preferredDefinition":"the elgibility criteria for CALGB 40601, the element of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial of a person who receives medical attention, care, or treatment in a clinical trials cooperative group supported by NCI.","longName":"C_PT_IN_CTE_40601_TP","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2625931","version":"1","preferredName":"Cancer and Leukemia Group B Patient Inclusion Clinical Trial Eligibility Criteria","preferredDefinition":"information relating to the elements of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial of a person who receives medical attention, care, or treatment in a clinical trials cooperative group supported by NCI.","longName":"CALGB_PT_INCL_CTEC","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2625929","version":"1","preferredName":"Cancer and Leukemia Group B Patient","preferredDefinition":"The Cancer and Leukemia Group B (CALGB) is a national clinical research group - network of 29 university medical centers, over 185 community hospitals and more than almost 3000 physicians - sponsored by the NCI, with its Central Office headquartered at the University of Chicago, and its Statistical Center located at Duke University, founded in 1955 with a goal of bringing together clinical and laboratory research.:A person who requires medical care.","longName":"C25442:C16960","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cancer and Leukemia Group B","conceptCode":"C25442","definition":"A national clinical research group - network of 29 university medical centers, over 185 community hospitals and more than almost 3000 physicians - sponsored by the NCI, with its Central Office headquartered at the University of Chicago, and its Statistical Center located at Duke University, founded in 1955 with a goal of bringing together clinical and laboratory research.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Patient","conceptCode":"C16960","definition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2DB1F788-C668-1ADE-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-04-09","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-04-09","modifiedBy":"ONEDATA","dateModified":"2007-04-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2518229","version":"1","preferredName":"Inclusion Clinical Trial Eligibility Criteria","preferredDefinition":"The addition of somebody or something to, or the presence of somebody or something in, a group or mixture, particularly, a passive, usually temporary, product of cell activity within the cytoplasm or nucleus.:Elements of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial.","longName":"C25532:C16112","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Inclusion Criteria","conceptCode":"C25532","definition":"Medical and/or social characteristics which are necessary for a subject to be allowed to participate in a clinical study, as outlined in the study protocol. Meeting inclusion criteria is not a sufficient condition for entry or recruitment of a subject into the study. Characteristics limiting the eligibility of a subject for the clinical study must be considered.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Clinical Trial Eligibility Criteria","conceptCode":"C16112","definition":"Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1CC96D39-08D4-6793-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-09-06","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-09-06","modifiedBy":"ONEDATA","dateModified":"2006-09-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2DB30129-B326-1BB8-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-05","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-04-09","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2680561","version":"1","preferredName":"40601 Inclusion Clinical Trial Eligibility Criteria Type","preferredDefinition":"the type of clinical trial eligibility inclusion criteria for a Cancer and Leukemia Group B protocol 40601.","longName":"40601_INCL_CTEC_TP","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"255","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Women or men at least 18 years of age","valueDescription":">= 18 years of age","ValueMeaning":{"publicId":"2625936","version":"1","preferredName":">= 18 years of age","longName":"2625936","preferredDefinition":">= 18 years of age","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2DB3082C-52A5-1CB2-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-04-09","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-04-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"39E37E1E-AB7A-277E-E044-0003BA3F9857","beginDate":"2007-04-09","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-09-11","modifiedBy":"CAMPBELB","dateModified":"2007-09-11","deletedIndicator":"No"},{"value":"Invasive breast cancer","valueDescription":"Invasive breast cancer","ValueMeaning":{"publicId":"2576315","version":"1","preferredName":"Invasive breast cancer","longName":"2576315","preferredDefinition":"A carcinoma that infiltrates the breast parenchyma.  The vast majority are adenocarcinomas arising from the terminal ductal lobular unit (TDLU).  Often, the invasive adenocarcinoma co-exists with ductal or lobular carcinoma in situ.  It is the most common carcinoma affecting women.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Invasive Breast Carcinoma","conceptCode":"C9245","definition":"A carcinoma that infiltrates the breast parenchyma.  The vast majority are adenocarcinomas arising from the terminal ductal lobular unit (TDLU).  Often, the invasive adenocarcinoma co-exists with ductal or lobular carcinoma in situ.  It is the most common carcinoma affecting women.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F728-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-09-21","endDate":null,"createdBy":"MAESKEB","dateCreated":"2005-09-21","modifiedBy":"ZHANGW","dateModified":"2021-08-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"39E2A0E8-D848-15B0-E044-0003BA3F9857","beginDate":"2007-09-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-09-11","modifiedBy":"ONEDATA","dateModified":"2007-09-11","deletedIndicator":"No"},{"value":"Serum Beta-HCG negative","valueDescription":"Beta-Hcg negative (in premenopausal women)","ValueMeaning":{"publicId":"2626074","version":"1","preferredName":"Beta-Hcg negative (in premenopausal women)","longName":"2626074","preferredDefinition":"Beta-Hcg negative (in premenopausal women)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2DC2B195-16D7-0602-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-04-10","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-04-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"39E37E1E-AB92-277E-E044-0003BA3F9857","beginDate":"2007-04-10","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-09-11","modifiedBy":"CAMPBELB","dateModified":"2007-09-11","deletedIndicator":"No"},{"value":"Total Bilirubin <= 1.5 x ULN unless due to Gilbert's Syndrome","valueDescription":"Bilirubin <= 1.5 x ULN unless due to Gilbert's Syndrome","ValueMeaning":{"publicId":"2626070","version":"1","preferredName":"Bilirubin <= 1.5 x ULN unless due to Gilbert's Syndrome","longName":"2626070","preferredDefinition":"Bilirubin <= 1.5 x ULN unless due to Gilbert's Syndrome","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2DC37927-6694-042B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-04-10","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-04-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"39E37E1E-AB9E-277E-E044-0003BA3F9857","beginDate":"2007-04-10","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-09-11","modifiedBy":"CAMPBELB","dateModified":"2007-09-11","deletedIndicator":"No"},{"value":"Clinical stage II-III operable invasive breast cancer with intent to perform surgical resection after neoadjuvant therapy","valueDescription":"Clinical stage II-III operable invasive breast cancer with intent to perform surgical resection after neoadjuvant therapy","ValueMeaning":{"publicId":"2680563","version":"1","preferredName":"Clinical stage II-III operable invasive breast cancer with intent to perform surgical resection after neoadjuvant therapy","longName":"2680563","preferredDefinition":"Clinical stage II-III operable invasive breast cancer with intent to perform surgical resection after neoadjuvant therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"39E297B8-45F6-2210-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-09-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-09-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"39E2A0E8-D85A-15B0-E044-0003BA3F9857","beginDate":"2007-09-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-09-11","modifiedBy":"ONEDATA","dateModified":"2007-09-11","deletedIndicator":"No"},{"value":"Multicentric or bilateral disease is eligible if target lesion meets eligibility criteria","valueDescription":"Multicentric or bilateral disease is eligible if target lesion meets eligibility criteria","ValueMeaning":{"publicId":"2680564","version":"1","preferredName":"Multicentric or bilateral disease is eligible if target lesion meets eligibility criteria","longName":"2680564","preferredDefinition":"Multicentric or bilateral disease is eligible if target lesion meets eligibility criteria","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"39E32104-D78A-1328-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-09-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-09-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"39E2A0E8-D86C-15B0-E044-0003BA3F9857","beginDate":"2007-09-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-09-11","modifiedBy":"ONEDATA","dateModified":"2007-09-11","deletedIndicator":"No"},{"value":"ECOG (Zubrod) Performance Status 0-1","valueDescription":"ECOG (Zubrod) PS <= 1; life expectancy >=12 wk","ValueMeaning":{"publicId":"2625937","version":"1","preferredName":"ECOG (Zubrod) PS <= 1; life expectancy >=12 wk","longName":"2625937","preferredDefinition":"ECOG (Zubrod) PS <= 1; life expectancy >=12 wk","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2DB32065-0BF3-1CC6-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-04-09","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-04-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"39E37E1E-ABC2-277E-E044-0003BA3F9857","beginDate":"2007-04-09","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-09-11","modifiedBy":"CAMPBELB","dateModified":"2007-09-11","deletedIndicator":"No"},{"value":"Tumors are HER2 positive as defined in section 4.3","valueDescription":"Tumors are HER2 positive as defined in section 4.3","ValueMeaning":{"publicId":"2680565","version":"1","preferredName":"Tumors are HER2 positive as defined in section 4.3","longName":"2680565","preferredDefinition":"Tumors are HER2 positive as defined in section 4.3","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"39E36197-53CF-18F7-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-09-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-09-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"39E2A0E8-D87E-15B0-E044-0003BA3F9857","beginDate":"2007-09-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-09-11","modifiedBy":"ONEDATA","dateModified":"2007-09-11","deletedIndicator":"No"},{"value":"ER/PgR status is known","valueDescription":"ER/PgR status is known","ValueMeaning":{"publicId":"2680566","version":"1","preferredName":"ER/PgR status is known","longName":"2680566","preferredDefinition":"ER/PgR status is known","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"39E2A070-4475-1461-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-09-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-09-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"39E2A0E8-D890-15B0-E044-0003BA3F9857","beginDate":"2007-09-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-09-11","modifiedBy":"ONEDATA","dateModified":"2007-09-11","deletedIndicator":"No"},{"value":"Target lesion in breast is > 1 cm by either clinical or radiographic measurement. Patients with axillary disease as only site are not eligible to participate","valueDescription":"Target lesion in breast is > 1 cm by either clinical or radiographic measurement. Patients with axillary disease as only site are not eligible to participate","ValueMeaning":{"publicId":"2680567","version":"1","preferredName":"Target lesion in breast is > 1 cm by either clinical or radiographic measurement. Patients with axillary disease as only site are not eligible to participate","longName":"2680567","preferredDefinition":"Target lesion in breast is > 1 cm by either clinical or radiographic measurement. Patients with axillary disease as only site are not eligible to participate","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"39E34A35-3F77-066D-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-09-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-09-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"39E2A0E8-D8A2-15B0-E044-0003BA3F9857","beginDate":"2007-09-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-09-11","modifiedBy":"ONEDATA","dateModified":"2007-09-11","deletedIndicator":"No"},{"value":"Patient consents to undergo pretreatment biopsy and to acquisition of tissue obtained at the time of surgery","valueDescription":"Patient consents to undergo pretreatment biopsy and to acquisition of tissue obtained at the time of surgery","ValueMeaning":{"publicId":"2680568","version":"1","preferredName":"Patient consents to undergo pretreatment biopsy and to acquisition of tissue obtained at the time of surgery","longName":"2680568","preferredDefinition":"Patient consents to undergo pretreatment biopsy and to acquisition of tissue obtained at the time of surgery","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"39E36197-53DF-18F7-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-09-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-09-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"39E2A0E8-D8B4-15B0-E044-0003BA3F9857","beginDate":"2007-09-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-09-11","modifiedBy":"ONEDATA","dateModified":"2007-09-11","deletedIndicator":"No"},{"value":"No prior chemotherapy, hormone therapy, biologic or radiation therapy with therapeutic intent for this cancer","valueDescription":"No prior chemotherapy, hormone therapy, biologic or radiation therapy with therapeutic intent for this cancer","ValueMeaning":{"publicId":"2680569","version":"1","preferredName":"No prior chemotherapy, hormone therapy, biologic or radiation therapy with therapeutic intent for this cancer","longName":"2680569","preferredDefinition":"No prior chemotherapy, hormone therapy, biologic or radiation therapy with therapeutic intent for this cancer","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"39E2A847-D8AC-145F-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-09-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-09-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"39E2A0E8-D8C6-15B0-E044-0003BA3F9857","beginDate":"2007-09-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-09-11","modifiedBy":"ONEDATA","dateModified":"2007-09-11","deletedIndicator":"No"},{"value":"No medication with known potential for interaction with lapatinib for at least 7 days prior to study entry","valueDescription":"No medication with known potential for interaction with lapatinib for at least 7 days prior to study entry","ValueMeaning":{"publicId":"2680570","version":"1","preferredName":"No medication with known potential for interaction with lapatinib for at least 7 days prior to study entry","longName":"2680570","preferredDefinition":"No medication with known potential for interaction with lapatinib for at least 7 days prior to study entry","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"39E34A35-3F87-066D-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-09-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-09-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"39E2A0E8-D8D8-15B0-E044-0003BA3F9857","beginDate":"2007-09-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-09-11","modifiedBy":"ONEDATA","dateModified":"2007-09-11","deletedIndicator":"No"},{"value":"Cardiac ejection fraction > 50% by echocardiogram or MUGA scan","valueDescription":"Cardiac ejection fraction > 50% by echocardiogram or MUGA scan","ValueMeaning":{"publicId":"2680571","version":"1","preferredName":"Cardiac ejection fraction > 50% by echocardiogram or MUGA scan","longName":"2680571","preferredDefinition":"Cardiac ejection fraction > 50% by echocardiogram or MUGA scan","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"39E29412-9CB9-0C4E-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-09-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-09-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"39E2AF0A-B369-1444-E044-0003BA3F9857","beginDate":"2007-09-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-09-11","modifiedBy":"ONEDATA","dateModified":"2007-09-11","deletedIndicator":"No"},{"value":"Patients not pregnant or nursing","valueDescription":"Patients not pregnant or nursing","ValueMeaning":{"publicId":"2680572","version":"1","preferredName":"Patients not pregnant or nursing","longName":"2680572","preferredDefinition":"Patients not pregnant or nursing","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"39E31BE6-0E16-13B4-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-09-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-09-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"39E2AF0A-B37B-1444-E044-0003BA3F9857","beginDate":"2007-09-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-09-11","modifiedBy":"ONEDATA","dateModified":"2007-09-11","deletedIndicator":"No"},{"value":"AST <= 2.5 x ULN","valueDescription":"AST <= 2.5 x ULN","ValueMeaning":{"publicId":"2680573","version":"1","preferredName":"AST <= 2.5 x ULN","longName":"2680573","preferredDefinition":"AST <= 2.5 x ULN","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"39E2A847-D8BC-145F-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-09-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-09-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"39E3366B-B282-145D-E044-0003BA3F9857","beginDate":"2007-09-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-09-11","modifiedBy":"ONEDATA","dateModified":"2007-09-11","deletedIndicator":"No"},{"value":"ALT <= 2.5 x ULN","valueDescription":"ALT <= 2.5 x ULN","ValueMeaning":{"publicId":"2680574","version":"1","preferredName":"ALT <= 2.5 x ULN","longName":"2680574","preferredDefinition":"ALT <= 2.5 x ULN","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"39E2B277-A1B4-14AE-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-09-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-09-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"39E3366B-B294-145D-E044-0003BA3F9857","beginDate":"2007-09-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-09-11","modifiedBy":"ONEDATA","dateModified":"2007-09-11","deletedIndicator":"No"},{"value":"ANC >= 1,000/mcl","valueDescription":"ANC >= 1,000/mcl","ValueMeaning":{"publicId":"2680575","version":"1","preferredName":"ANC >= 1,000/mcl","longName":"2680575","preferredDefinition":"ANC >= 1,000/mcl","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"39E32104-D79A-1328-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-09-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-09-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"39E34A35-3F9E-066D-E044-0003BA3F9857","beginDate":"2007-09-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-09-11","modifiedBy":"ONEDATA","dateModified":"2007-09-11","deletedIndicator":"No"},{"value":"Platelet count >= 100,000/mm^3","valueDescription":"Platelet count >= 100,000/mm^3","ValueMeaning":{"publicId":"2680576","version":"1","preferredName":"Platelet count >= 100,000/mm^3","longName":"2680576","preferredDefinition":"Platelet count >= 100,000/mm^3","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"39E34F97-70CA-132A-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-09-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-09-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"39E34A35-3FB0-066D-E044-0003BA3F9857","beginDate":"2007-09-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-09-11","modifiedBy":"ONEDATA","dateModified":"2007-09-11","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CALGB CRF:Cancer and Leukemia Group B Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"39E37E17-6BF6-2672-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-09-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-09-11","modifiedBy":"SHIDED","dateModified":"2011-04-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"Eligibility criteria","type":"Preferred Question Text","description":"Eligibility criteria","url":null,"context":"CTEP"}],"origin":"CALGB CRF:Cancer and Leukemia Group B Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"39E31BE6-0DF3-13B4-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-09-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-09-11","modifiedBy":"CAMPBELB","dateModified":"2011-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}